Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), will host a second quarter 2026 business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. Management will review business operations, growth strategy, and second quarter 2026 financial results. The live webcast and a 30-day replay will be available in the investor relations section of luciddx.com, with telephone access for U.S. and international callers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call and Webcast at 8:30 AM ET

NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2026 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-second-quarter-2026-business-update-conference-call-and-webcast-on-august-13-2026-302838737.html

SOURCE Lucid Diagnostics

FAQ

When is the Lucid Diagnostics (NASDAQ: LUCD) Q2 2026 business update conference call?

The Lucid Diagnostics Q2 2026 business update call is scheduled for Thursday, August 13, 2026, at 8:30 AM ET. According to Lucid Diagnostics, the event will cover a business update, operations, growth strategy and second quarter 2026 financial results.

How can investors access the Lucid Diagnostics (LUCD) Q2 2026 webcast on August 13, 2026?

Investors can access the Lucid Diagnostics Q2 2026 webcast through the investor relations section of luciddx.com. According to Lucid Diagnostics, a live webcast will be available, and a replay will remain accessible on the website for 30 days following the call.

What are the dial-in numbers for the Lucid Diagnostics (LUCD) August 13, 2026 conference call?

U.S.-based investors should dial 1-800-836-8184, and international listeners should dial 1-646-357-8785. According to Lucid Diagnostics, callers must provide the conference name “Lucid Diagnostics Business Update” to join the second quarter 2026 business update call.

Who will present during the Lucid Diagnostics Q2 2026 business update call on August 13, 2026?

According to Lucid Diagnostics, Chairman and CEO Lishan Aklog, M.D. will provide a business update, and CFO Dennis McGrath will discuss second quarter 2026 financial results. Together, they will address operations, growth strategy and financial performance on the August 13, 2026 call.

Will a replay be available for the Lucid Diagnostics (LUCD) Q2 2026 business update webcast?

Yes, a replay of the Lucid Diagnostics Q2 2026 business update webcast will be available for 30 days. According to Lucid Diagnostics, investors can access the replay in the investor relations section of the company’s website at luciddx.com following the live call.